Moderator
Paul Scuffham, PhD, Griffith University, Gold Coast, Australia
Speakers
Bruce Crawford, MA, MPH, Vista Health Japan KK, Tokyo, Japan; Jing Wu, PhD, Tianjin University, Tianjin, China; Ji-Hye Byun, PhD, HEALTH INSURANCE REVIEW & ASSESSMENT SERVICE, WONJU-SI, Korea; Azuana Ramli, PhD, Ministry of Health, Petaling Jaya, Malaysia; Patrice Verpillat, MD, MPH, PhD, European Medicines Agency (EMA), Amsterdam, Netherlands
The use of real-world evidence (RWE) continues to increase but has yet to reach its potential and maximize value. There is a long history of RWE in post-market reviews to monitor drug safety, effectiveness, and value-based pricing; however, RWE for decision-making such as drug approvals, health technology assessment and clinical practice remains in its development. Access to large – population level - real world databases is fundamental as is developing robust methods for standardized analysis of data and collaboration across jurisdictions remains in its infancy.
This plenary panel explores the future for RWE in HEOR and addresses questions around what do we, as HEOR experts, need to do to develop and optimize the use of RWE? How should we go about getting RWE into decision-making and clinical practice? How we should leverage AI alongside RWD to generate RWE for valuable insights? What role does RWE play in advancing regulatory and HTA harmonization in the region?
Code
28b